What is the confirmatory second test and how does it raise specificity to 99.9%?

When any of the three cancer miRNA markers in an initial OncuraKit analysis exceeds the 1.5× HL threshold, Yenos automatically performs a second independent nanopore analysis on the same preserved urine sample. For a true cancer signal, the same marker(s) will be elevated on both independent measurements — because the biological overexpression is real and consistent. For a rare false positive from a technical artifact or biological fluctuation, the second test is very likely to be normal. Two independent elevated results on the same sample indicate a true cancer-associated miRNA overexpression with very high confidence. The published Yenos data shows that applying this two-test criterion reduces the false positive rate to below 0.1% — equivalent to a specificity of >99.9%.